TY - CHAP
T1 - Mouse models of pancreatic cancer
AU - Ostapoff, Katherine T.
AU - Dellinger, Michael T.
AU - Awasthi, Niranjan
AU - Brekken, Rolf A.
AU - Schwarz, Roderich E.
N1 - Funding Information:
This work was supported by NIH grants DK-61215 and DK-56211 and by the Paul K. Neumann Professorship in Pancreatic Cancer at Johns Hopkins University. The author wishes to thank Nabeel Bardeesy, Robert Coffey, Paul Grippo, Sunil Hingorani, Ralph Hruban, Brian Lewis, Dan Longnecker, Anirban Maitra, Anil Rustgi, Eric Sandgren, Roland Schmid, and David Tuveson for many stimulating discussions regarding this topic.
Publisher Copyright:
© Springer Science+Business Media Dordrecht 2013.
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Pancreatic ductal adenocarcinoma (PDAC) is a disease characterized by aggressive tumor biology, desmoplasia and chemoresistance. Given the insidious nature of its onset, multiple models have been developed to study progression from in situ lesions (PanIN) to PDAC in transgenic mouse models. These have been developed using known mutations that are present in human tumors including K-ras, p53, DPC4, CDNK2a, p16 and Brca2. The metastatic character of each of these models is variable and described here. Metastasis to the lymph nodes, liver and peritoneum are also prominent features of PDAC. Syngeneic models and xenograft models (i.e. orthotopic, direct xenograft and metastatic models) are also used to study primary tumor development and metastatic disease and are described.This chapter seeks to describe murine models of experimental PDAC that are currently used to investigate mechanisms of carcinogenesis and metastatic progression, individual risk factors, tumor biology aspects, mechanisms of in vivo chemoresistance, analysis of therapeutic targets and experimental therapies.
AB - Pancreatic ductal adenocarcinoma (PDAC) is a disease characterized by aggressive tumor biology, desmoplasia and chemoresistance. Given the insidious nature of its onset, multiple models have been developed to study progression from in situ lesions (PanIN) to PDAC in transgenic mouse models. These have been developed using known mutations that are present in human tumors including K-ras, p53, DPC4, CDNK2a, p16 and Brca2. The metastatic character of each of these models is variable and described here. Metastasis to the lymph nodes, liver and peritoneum are also prominent features of PDAC. Syngeneic models and xenograft models (i.e. orthotopic, direct xenograft and metastatic models) are also used to study primary tumor development and metastatic disease and are described.This chapter seeks to describe murine models of experimental PDAC that are currently used to investigate mechanisms of carcinogenesis and metastatic progression, individual risk factors, tumor biology aspects, mechanisms of in vivo chemoresistance, analysis of therapeutic targets and experimental therapies.
UR - http://www.scopus.com/inward/record.url?scp=84956525625&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84956525625&partnerID=8YFLogxK
U2 - 10.1007/978-94-007-7835-1_4
DO - 10.1007/978-94-007-7835-1_4
M3 - Chapter
AN - SCOPUS:84956525625
SN - 9789400778344
SP - 57
EP - 91
BT - Experimental Metastasis
PB - Springer Netherlands
ER -